TWI922719B - 高強度他汀弱反應物之治療 - Google Patents
高強度他汀弱反應物之治療Info
- Publication number
- TWI922719B TWI922719B TW111127830A TW111127830A TWI922719B TW I922719 B TWI922719 B TW I922719B TW 111127830 A TW111127830 A TW 111127830A TW 111127830 A TW111127830 A TW 111127830A TW I922719 B TWI922719 B TW I922719B
- Authority
- TW
- Taiwan
- Prior art keywords
- pharmaceutically acceptable
- therapy
- hydrate
- oxietraspirine
- ldl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21187721 | 2021-07-26 | ||
| EP21187721.2 | 2021-07-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202310842A TW202310842A (zh) | 2023-03-16 |
| TWI922719B true TWI922719B (zh) | 2026-04-21 |
Family
ID=77358089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111127830A TWI922719B (zh) | 2021-07-26 | 2022-07-25 | 高強度他汀弱反應物之治療 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230041138A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4376832B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024527023A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240040767A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117940125A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022320869A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3227153A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK4376832T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3071242T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI4376832T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL310115A (cg-RX-API-DMAC7.html) |
| LT (1) | LT4376832T (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024001170A (cg-RX-API-DMAC7.html) |
| PL (1) | PL4376832T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT4376832T (cg-RX-API-DMAC7.html) |
| TW (1) | TWI922719B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023006657A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12006305B2 (en) | 2022-07-05 | 2024-06-11 | Newamsterdam Pharma B.V. | Salts of obicetrapib and processes for their manufacture and intermediates thereof |
| WO2025146415A1 (en) * | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Improvement in atherosclerotic plaque characteristics with obicetrapib |
| EP4746866A1 (en) * | 2024-09-17 | 2026-05-27 | NewAmsterdam Pharma B.V. | Obicetrapib for use in methods for treating a subject having heterozygous familial hypercholesterolemia (hefh) and/or atherosclerotic cardiovascular disease (ascvd) |
| WO2026146129A1 (en) * | 2025-01-02 | 2026-07-09 | Newamsterdam Pharma B.V. | Magnesium salts of obicetrapib |
| WO2026146132A1 (en) * | 2025-01-02 | 2026-07-09 | Newamsterdam Pharma B.V. | Salts of obicetrapib |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201613598A (en) * | 2014-08-28 | 2016-04-16 | Dezima Pharma B V | Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and HMG CoA reductase inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA90269C2 (ru) | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| UY30244A1 (es) | 2006-03-30 | 2007-11-30 | Tanabe Seiyaku Co | Un proceso para preparar derivados de tetrahidroquinolina |
| KR20150028233A (ko) | 2012-05-07 | 2015-03-13 | 옴테라 파마슈티칼스, 인크. | 스타틴 및 오메가-3 지방산의 조성물 |
| CN107108558B (zh) | 2014-08-12 | 2019-11-19 | 狄智玛制药私人有限公司 | 制备用于制备四氢喹啉衍生物的合成中间体的方法 |
-
2022
- 2022-07-25 IL IL310115A patent/IL310115A/en unknown
- 2022-07-25 FI FIEP22754412.9T patent/FI4376832T3/fi active
- 2022-07-25 CN CN202280057367.XA patent/CN117940125A/zh active Pending
- 2022-07-25 KR KR1020247005859A patent/KR20240040767A/ko active Pending
- 2022-07-25 JP JP2024504808A patent/JP2024527023A/ja active Pending
- 2022-07-25 ES ES22754412T patent/ES3071242T3/es active Active
- 2022-07-25 MX MX2024001170A patent/MX2024001170A/es unknown
- 2022-07-25 CA CA3227153A patent/CA3227153A1/en active Pending
- 2022-07-25 TW TW111127830A patent/TWI922719B/zh active
- 2022-07-25 DK DK22754412.9T patent/DK4376832T3/da active
- 2022-07-25 LT LTEPPCT/EP2022/070780T patent/LT4376832T/lt unknown
- 2022-07-25 US US17/873,009 patent/US20230041138A1/en active Pending
- 2022-07-25 PL PL22754412.9T patent/PL4376832T3/pl unknown
- 2022-07-25 EP EP22754412.9A patent/EP4376832B1/en active Active
- 2022-07-25 AU AU2022320869A patent/AU2022320869A1/en active Pending
- 2022-07-25 EP EP26160076.1A patent/EP4789665A1/en active Pending
- 2022-07-25 PT PT227544129T patent/PT4376832T/pt unknown
- 2022-07-25 WO PCT/EP2022/070780 patent/WO2023006657A1/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201613598A (en) * | 2014-08-28 | 2016-04-16 | Dezima Pharma B V | Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and HMG CoA reductase inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| 期刊 Kastelein JJ, Besseling J, Shah S,et al. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study Lancet 385(9983) 2015/03/03 2153-61 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024527023A (ja) | 2024-07-19 |
| CA3227153A1 (en) | 2023-02-02 |
| AU2022320869A1 (en) | 2024-02-01 |
| TW202310842A (zh) | 2023-03-16 |
| CN117940125A (zh) | 2024-04-26 |
| US20230041138A1 (en) | 2023-02-09 |
| DK4376832T3 (da) | 2026-06-15 |
| WO2023006657A1 (en) | 2023-02-02 |
| PT4376832T (pt) | 2026-06-11 |
| EP4789665A1 (en) | 2026-08-12 |
| PL4376832T3 (pl) | 2026-08-10 |
| IL310115A (en) | 2024-03-01 |
| LT4376832T (lt) | 2026-07-10 |
| KR20240040767A (ko) | 2024-03-28 |
| ES3071242T3 (en) | 2026-06-22 |
| MX2024001170A (es) | 2024-05-14 |
| FI4376832T3 (fi) | 2026-06-10 |
| EP4376832A1 (en) | 2024-06-05 |
| EP4376832B1 (en) | 2026-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6419927B2 (ja) | 対象の高感度(hs−crp)のレベルを低下させる組成物および方法 | |
| EP4376832B1 (en) | Obicetrapib for use in treating of cardiovascular disease (cvd) in his hyporesponders | |
| US10966968B2 (en) | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof | |
| JP6196225B2 (ja) | 糖尿病新規発症低減用組成物 | |
| ES2862336T3 (es) | Composición farmacéutica que comprende ácido eicosapentaenoico y ácido nicotínico y métodos de uso de la misma | |
| JP7862336B2 (ja) | 心血管疾患を処置するか又は心血管疾患のリスクを低減させるためのetc1002及び1種以上のスタチンを含む固定用量組合せ物 | |
| US20150073050A1 (en) | Co-administration of omeprazole and eicosapentaenoic acid or a derivative thereof | |
| US20170172954A1 (en) | Treatment of NASH with Gemcabene | |
| CN102413825A (zh) | 含有epa和心血管剂的药物组合物以及使用其的方法 | |
| KR20200074259A (ko) | 고혈중 고감도 c반응성 단백질 환자의 심혈관 질병 1차 예방제 | |
| CA3147657A1 (en) | Ethyl eicosapentaenoate for maintaining ldl control | |
| Vogt et al. | Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study | |
| KR101494067B1 (ko) | 부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과 연관된 질환 또는 질병의 치료 방법 | |
| TWI741379B (zh) | 藥物組成物與包含膽固醇酯轉移蛋白抑制劑和HMG CoA還原酶抑制劑的治療組合 | |
| TWI651086B (zh) | 用以治療或預防心血管疾病之膽固醇酯轉蛋白質(cetp)抑制劑及包含該抑制劑之醫藥組成物 | |
| ES2811302T3 (es) | Uso de inhibidores de la PDE4 para la profilaxis y/o la terapia de la dislipoproteinemia y trastornos relacionados | |
| JP6227535B2 (ja) | 脂質異常症の予防又は治療薬 | |
| CN1437484A (zh) | 含有β-受体阻滞剂和任选的降胆固醇剂的新型制剂 | |
| NZ763702B2 (en) | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity | |
| NZ763702A (en) | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |